GlassScriptPhysician profile
Joy T Aden
NPI 1114936408
$2,718.35
in general payments reported to CMS, 2019-2025
25 companies · $601 in 2025
The $601 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $70.76 · 2021: $169 · 2022: $556 · 2023: $683 · 2024: $347 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.94 | 2019-2024 | Lo Loestrin Fe, Liletta |
| Mayne Pharma Commercial LLC | $426.51 | 2021-2025 | |
| Hologic Sales and Service, LLC | $401.55 | 2023-2025 | Aptima |
| Astellas Pharma US INC | $258.13 | 2022-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $218.15 | 2019-2024 | |
| Daiichi Sankyo INC. | $176.10 | 2020-2022 | |
| Biogen, INC. | $142.11 | 2024-2025 | Zurzuvae |
| Organon LLC | $88.71 | 2021-2025 | Nexplanon |
| Exeltis, USA INC. | $71.40 | 2023-2025 | Slynd |
| Millicent US INC | $57.11 | 2020-2025 | Intrarosa, Femlyv |
| Innovation Technologies INC | $44.26 | 2024 | Irrisept |
| Ethicon US, LLC | $43.63 | 2022 | |
| Coopersurgical, INC. | $33.63 | 2019-2024 | Paragard T 380a |
| Duchesnay USA Incorporated | $27.85 | 2019 | |
| Avion Pharmaceuticals | $25.06 | 2020-2023 | Balcoltra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.05 | 2023 | Myfembree |
| Scynexis, INC. | $17.50 | 2022 | |
| Therapeuticsmd, INC. | $15.06 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.78 | 2025 | Exparel |
| Agile Therapeutics, INC. | $13.93 | 2021 | |
| Merck Sharp & Dohme LLC | $13.77 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.71 | 2019 | |
| Convatec INC. | $13.06 | 2023 | |
| Lupin INC. | $12.94 | 2020 | |
| Meditrina | $9.41 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Aden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.